Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Phase II study of profiromycin vs mitomycin-C utilizing acute intermittent schedules.

Baker LH, Izbicki RM, Vaitkevicius VK.

Med Pediatr Oncol. 1976;2(2):207-13.

PMID:
958162
2.

Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.

Haffty BG, Son YH, Wilson LD, Papac R, Fischer D, Rockwell S, Sartorelli AC, Ross D, Sasaki CT, Fischer JJ.

Radiat Oncol Investig. 1997;5(5):235-45.

PMID:
9372546
3.

Phase I trial of ftorafur combined with mitomycin C or methyl-CCNU in gastrointestinal cancers.

Buroker T, Baker L, Correa J, Schwartz LA, Vailtkevicius VK.

Cancer Treat Rep. 1977 May-Jun;61(3):463-7.

PMID:
326403
4.

Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas.

Buroker TR, Kim PN, Baker LH, Ratanatharathron V, Wojtaszak B, Vaitkevicius VK.

Med Pediatr Oncol. 1978;4(1):35-42.

PMID:
342890
5.

[Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].

Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Shibuya M, Shimabukuro Z.

Gan To Kagaku Ryoho. 1983 Mar;10(3):834-9. Japanese.

PMID:
6882001
6.
7.

Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.

Redman C, Lawton F, Stuart N, O'Brien M, Buxton J, Mould J, Chetiyawardana A, Crawford M, Patterson M, Sykes V, et al.

Cancer Chemother Pharmacol. 1989;23(1):51-3.

PMID:
2491794
8.

A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.

Crino L, Tonato M, Darwish S, Meacci ML, Corgna E, Di Costanzo F, Buzzi F, Fornari G, Santi E, Ballatori E, et al.

Cancer Chemother Pharmacol. 1990;26(1):52-6.

PMID:
2157554
9.

Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.

Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB, Rockwell S, Sartorelli AC, Ross DA, Sasaki CT, Fischer JJ.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):119-28.

PMID:
15629602
12.

A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.

Hoskins PJ, McMurtrie E, Swenerton KD.

Am J Clin Oncol. 1990 Oct;13(5):416-9.

PMID:
2220661
13.

Mitomycin-C in breast cancer.

Hortobagyi GN.

Semin Oncol. 1985 Dec;12(4 Suppl 6):65-70. Review.

PMID:
3936183
14.

A phase I-II study of continuous 5-day infusion mitomycin-C.

Yap HY, Valdivieso M, Blumenschein G, Hortobagyi G, Bedikian A.

Am J Clin Oncol. 1983 Feb;6(1):109-12.

PMID:
6404154
15.

Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.

Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H, Hoshi A.

Jpn J Clin Oncol. 1985 Mar;15(1):61-5.

PMID:
3981815
16.

Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic carcinoma. Severe pulmonary toxicity from q 3 weekly mitomycin C.

Doyle LA, Ihde DC, Carney DN, Bunn PA, Cohen MH, Matthews MJ, Puffenbarger R, Cordes RS, Minna JD.

Am J Clin Oncol. 1984 Dec;7(6):719-24.

PMID:
6442103
17.

[A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].

Takahashi K, Yokoyama M, Takahashi H, Wakui A.

Gan To Kagaku Ryoho. 1985 Sep;12(9):1787-93. Japanese.

PMID:
4037809
18.

Phase II study of low-dose mitomycin in patients with ovarian cancer previously treated with chemotherapy.

Creech RH, Shah MK, Catalano RB, Dierks K, Dayal H, Goldberg-Alberts R.

Cancer Treat Rep. 1985 Nov;69(11):1271-3.

PMID:
4092190
19.

[Chemotherapy of gastrointestinal tumors (review of the literature)].

Mayr AC.

Onkologie. 1978 Dec;1(6):248-56. Review. German.

PMID:
83561
20.

Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer.

Alberts DS, Garcia-Kendall D, Surwit EA.

Semin Oncol. 1988 Jun;15(3 Suppl 4):22-6.

PMID:
3134694

Supplemental Content

Support Center